Servier
Description
Founded to serve healthcare, Servier is an international pharmaceutical group governed by a Foundation, which aspires to have a significant societal impact for patients and for a sustainable world. Its unique governance model enables it to fully serve its vocation with a long-term vision: to be committed to therapeutic progress for the benefit of patients. The Group's 21,900 employees are committed to this shared vocation, a source of daily inspiration.
A world leader in cardiology, Servier's ambition is to become a focused and innovative player in oncology, targeting cancers that are difficult to treat. This is why the Group devotes over 70% of its R&D budget to the development of innovative, targeted oncology therapies.
Neuroscience and immuno-inflammatory diseases represent a future growth driver. In these fields, Servier focuses on a limited number of specific pathologies in which precise patient characterization makes it possible to offer a targeted therapeutic response, thanks to precision medicine.
To promote access to quality healthcare for all, and at lower cost, the Group also offers a range of generic medicines covering the majority of pathologies, backed by strong brands in France, Eastern Europe, Brazil and Nigeria.
In all these areas, the Group integrates the patient's voice at every stage of the drug life cycle.
Headquartered in France, Servier boasts a solid geographical presence in over 150 countries, and in 2023, achieved sales of 5.3 billion euros.